Infliximab could restore disease response after drug holiday
Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows.
Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis (UC) recapture and maintain disease control.
The analysis evaluated the efficacy and safety of starting SC infliximab 240mg in patients, randomised to the placebo maintenance arm in the Phase III LIBERTY studies. These patients had previously completed IV infliximab induction and subsequently experienced a drug holiday of 16 weeks or more before starting SC infliximab due to disease progression.
Among 51 CD and 77 UC patients who initiated treatment with SC infliximab, clinical response was observed early by 8±2 weeks and was maintained through the study. At the end of the treatment, 61.1% in CD and 65.2% in UC patients achieved faecal calprotectin remission, and 64.0% in CD and 68.8% in UC patients achieved endoscopic response or improvement.
“As immunogenicity is the most significant concern when restarting treatment with infliximab after an interruption, these results suggest that treatment persistence was maintained even in patients with immunogenicity,” said Dr Marla Dubinsky, Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine at Mount Sinai.
“It’s reassuring to see that not only can we effectively recapture disease control with a convenient subcutaneous option, but that this response was seen early and was shown to be maintained through Week 102 in a post-hoc analysis from the pivotal LIBERTY studies.
“This is a significant finding for patients, as it offers a potentially reliable strategy for providers and transformative opportunity for patients to manage their IBD journey even when treatment is interrupted.”
